PhD Scientific Days 2025

Poster Session II. - J: Theoretical and Translational Medicine

The Role of Dual Oxidase 1 Enzyme in Cyclophosphamide-Induced Cystitis in Mice

Előadó neve

Dr. Borsodi Kinga, PhD

Neptun code

IWA1O0

Előadó munkahelye

Institute of Translational Medicine

Előadó telefonszáma

+36205740715

Előadó e-mail címe

kingaborsodi@gmail.com

Az előadás címe

The Role of Dual Oxidase 1 Enzyme in Cyclophosphamide-Induced Cystitis in Mice

Szerző(k) neve és munkahelye

Kinga Borsodi¹, Ádám Lénárt², Helga Balla¹, Péter József Molnár², Kamilla Makk³, Gábor Sirokmány⁴, Miklós Geiszt⁴, Zoltán Benyó³

1: Institute of Translational Medicine
2: Department of Urology, Semmelweis University, Budapest
3: Institute of Translational Medicine, Semmelweis University, Budapest
4: Department of Physiology, Semmelweis University, Budapest

Bemutatás módja

Poszter

Szekció

Poster Session II. - J: Theoretical and Translational Medicine

Language of the presentation

English

Preferred session

Theoretical and Translational Medicine

Összefoglaló szövege

Introduction: Overactive bladder (OAB) syndrome is commonly associated with oxidative stress and elevated hydrogen peroxide (H₂O₂). The cyclophosphamide (CYP)-induced cystitis mouse effectively mimics the symptoms of OAB. The dual oxidase 1 (DUOX1) enzyme is abundantly expressed in the urinary bladder, and it is often upregulated in conditions linked to oxidative stress. This suggests a potential role for DUOX1 enzyme in the pathomechanism of OAB.
Aims: This study aimed to investigate the role of DUOX1 enzyme in the CYP-induced mouse model of OAB.
Methods: We conducted in vivo cystometric measurements and void spot assays (VSA) on 90-120-day-old female DUOX1 wild type (WT) and DUOX1 knockout (KO) mice. OAB symptoms were induced via intraperitoneal CYP-administration (200 mg/kg). Bladders were filled transurethrally with physiological saline solution via a catheter before and 24 hours after CYP-treatment. The following parameters were assessed: voiding contraction (VC) frequency and amplitude, bladder capacity at first VC, bladder capacity at first voiding, average capacity before VC. In case of VSA, we investigated the size, number and location of void spots on filter paper before and after CYP-treatment.
Result: CYP-treatment increased bladder contractile activity in WT mice. We observed a higher VC frequency, reduced bladder capacity at first VC and first voiding and decreased average bladder capacity before VC. The amplitude of VCs remained unchanged. VSA measurements supported our findings, showing smaller and more frequent urine spots after CYP-treatment in WT mice. In contrast, CYP-treatment in DUOX1-KO mice did not induce bladder hyperactivity. All cystometric and VSA parameters were similar to those measured before the CYP-treatment.
Conclusion: CYP-treatment resulted in OAB-like symptoms in DUOX1-WT mice, as demonstrated by both cystometric parameters and VSA parameters. However, the absence of DUOX1 enzyme prevented the development of bladder hyperactivity following CYP-treatment. These findings suggest that DUOX1 plays a critical role in the pathophysiology of CYP-induced OAB Thus, DUOX1 enzyme serves as a potential target and we are planning further research to better understand its role in bladder dysfunction.
Funding: K-135683, K-139230, PD-143327; and Predoctoral Fellowship 2024/25, TKP2021-EGA-25 from the Hungarian NRDIO

University

Semmelweis University

Supervisor

Zoltán Benyó, MD, DSc

Publication of my abstract

I do not give consent to the publication of my abstract on the website of the congress.

phd.section.field

after finishing doctoral studies with absolutorium (PhD)

Kind

Szabad

Status

elfogadva

Accepted presentation method

poszter

Előadás fájl jóváhagyás

nem rendelkezett róla

Előadó

4811

Start

18:36

End

18:42